Clinical Trials
Vertex aims for broad kidney disease label ahead of key readout next year
Endpoints News
1d ago
Vertex Pharmaceuticals reported that an experimental kidney disease drug called inaxaplin improved measures on a urine test in two different patient populations, raising optimism ahead of the company’s upcoming pivotal readout. ...
Discussion
Sign in to join the discussion. Comments loading…